Onasemnogene abeparvovec Injectable bulk supplier for pharma manufacturers

Onasemnogene Abeparvovec Injectable Suppliers & Bulk Manufacturers

Available Forms: Injectable gene therapy

Available Strengths: Single-dose IV infusion providing 6 x 10^13 vector genomes (vg) per patient

Reference Brands: Zolgensma(US & EU)

Onasemnogene abeparvovec (Zolgensma) delivers a functional copy of the SMN1 gene via gene therapy, increasing SMN protein production. It improves motor function, prolongs survival, and reduces the need for ventilatory support in SMA patients. Offers a one-time, lifelong treatment for early intervention in SMA.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Onasemnogene abeparvovec (Zolgensma) is regulated in both the US and EU, supported by dossiers demonstrating safety, efficacy, and manufacturing quality following GMP standards. In the US, FDA approval involved extensive clinical trials, safety evaluations, and GMP compliance. In the EU, CE marking certifies conformity with MDR standards for pediatric spinal muscular atrophy (SMA) treatment. These therapies undergo validation, stability testing, and audits, with detailed documentation including clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and latest regulatory updates, visit Pharmatradz. Ensuring compliance grants access to innovative, life-changing gene therapy for SMA worldwide, supporting early intervention and improved long-term outcomes.

Onasemnogene Abeparvovec Injectable — third party manufacturing & bulk supply

Onasemnogene Abeparvovec Injectable is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Onasemnogene Abeparvovec Injectable is supplied as Injectable gene therapy — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Onasemnogene Abeparvovec Injectable listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Onasemnogene Abeparvovec Injectable →

Back to Listing

Frequently Asked Questions

Onasemnogene abeparvovec Injectable is listed as Injectable gene therapy in Single-dose IV infusion providing 6 x 10^13 vector genomes (vg) per patient. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Onasemnogene abeparvovec Injectable is referenced against Zolgensma(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.